Status of Chronic Liver Disease in Hepatitis C Virus (HCV) Patients Coinfected With Human Immunodeficiency Virus (HIV) in Andalusia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

2800 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-09-30

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the current situation and follow-up of chronic hepatitis C virus (HCV) infection in patients co-infected with human immunodeficiency virus (HIV) in Andalusia.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In subjects co-infected with HIV, treatment of chronic HCV infection is particularly complex and requires considerable resources, including a very high cost is likely to increase with new antivirals.

A precise knowledge of the situation in each hospital would facilitate adequate provision of personal and material resources needed to adequately address this disease in each center and in the Community as a whole. Because all or the vast majority of patients coinfected HIV / HCV are staffed by specialists who are part of Hepavir group and / or Sociedad Andaluza de Enfermedades Infecciosas (SAEI), they are ideal for carrying out this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Hepatitis C Human Immunodeficiency Virus (HIV)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients over 18 with HIV infection and active chronic hepatitis or SVR after treatment.

Exclusion Criteria

* None

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Antonio Rivero Juárez

Role: PRINCIPAL_INVESTIGATOR

Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Blanca Quijano Ruiz, Pharmacist

Role: CONTACT

Phone: (+34) 677 90 65 67

Email: [email protected]

References

Explore related publications, articles, or registry entries linked to this study.

Rivero-Juarez A, Guijo-Rubio D, Tellez F, Palacios R, Merino D, Macias J, Fernandez JC, Gutierrez PA, Rivero A, Hervas-Martinez C. Using machine learning methods to determine a typology of patients with HIV-HCV infection to be treated with antivirals. PLoS One. 2020 Jan 10;15(1):e0227188. doi: 10.1371/journal.pone.0227188. eCollection 2020.

Reference Type DERIVED

PMID: 31923277 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HEP-COI-1-2014

Identifier Type: -

Identifier Source: org_study_id